Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.
You may also be interested in...
Rigel Mulls Next Steps After Fostamatinib Fails In Kidney Disease
Rigel sees positive signs for Tavalisse in failed mid-stage study in autoimmune nephropathy, but investors don't share the optimism, sending the stock down almost 14% on the news.
Deal Watch: Immuno-Oncology Double-Header At Bristol With Rigel, Flexus Deals
Valeant jumps back into M&A, acquiring Salix after wholesale inventory issues discouraged other potential buyers. Merck more or less options a pipeline with its five-year R&D collaboration with NGM Pharma.
Deals Of The Week Searches For Meaning In Deal Break-Ups
Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.